List of works - Min H Kang

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma

scientific article

A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).

scientific article published on September 2001

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

scientific article

Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression

scientific article

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

scientific article published on 29 May 2007

Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.

scientific article published on 17 October 2012

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy

scientific article

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

scientific article published on 18 December 2018

C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines.

scientific article

Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines.

scientific article

Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia

scientific article published on 11 September 2018

Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

scientific article

Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines

scientific article published on 24 September 2018

Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia

scientific article published on 01 February 2019

DNA-PK as an Emerging Therapeutic Target in Cancer

scientific article published on 17 July 2019

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

scientific article published on 30 March 2011

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

scientific article published on 5 August 2016

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

scientific article published on 7 February 2012

Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program ⬇️

scientific article published on December 1, 2010

Fenretinide cytotoxicity is independent of both constitutive and pharmacologically modulated glutathione levels in pediatric acute lymphoblastic leukemia cells cultured at hypoxia.

scientific article published on June 2012

Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure

scientific article

Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models

scientific article published on 04 September 2019

Hydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma

scientific article published on 22 February 2019

Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor

scientific article published on 15 March 2016

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

scientific article published on 30 May 2016

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

scientific article

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

scientific article

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

scientific article

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

scientific article published on 16 August 2011

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

scientific article

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

scientific article published on 18 November 2014

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

scientific article published on 16 June 2011

Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.

scientific article published on 17 September 2017

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

scientific article published on 2 November 2011

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

scientific article

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

scientific article published on February 2010

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

scientific article published on 27 September 2014

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

scientific article

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.

scientific article published on 7 July 2015

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

scientific article published on 21 September 2016

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

scientific article

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

scientific article published on December 2010

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.

scientific article published on 26 October 2013

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

scientific article published on 15 September 2011

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

scientific article published on 27 October 2016

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

scientific article

Initial testing of aplidin by the pediatric pre-clinical testing program.

scientific article published on September 2009

Initial testing of lenalidomide by the pediatric preclinical testing program

scientific article published on 25 February 2011

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

scientific article

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

scientific article

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

scientific article

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

scientific article

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

scientific article published on 19 October 2011

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

scientific article

Initial testing of topotecan by the pediatric preclinical testing program.

scientific article

MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma

scientific article published on 14 May 2020

Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma

scientific article

Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235

scientific article

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

scientific article

P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.

scientific article

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

scientific article

Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.

scientific article

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial

scientific article

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial

scientific article published on 30 March 2018

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

scientific article

Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas

scientific article published on 01 March 2011

Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration

scientific article

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.

scientific article

Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies.

scientific article published on 23 January 2017

Reversal of multidrug resistance: lessons from clinical oncology.

scientific article

Role of OCT4 in cancer stem-like cells and chemotherapy resistance

scientific article published on 21 March 2019

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

scientific article

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

scientific article

Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis.

scientific article published on 3 December 2011

Taxanes in hormone-refractory prostate cancer.

scientific article

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

scientific article published on 18 November 2011

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

scientific article

The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.

scientific article published in June 2001

The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma

scientific article

pH gradient-liquid chromatography tandem mass spectrometric assay for determination of underivatized polyamines in cancer cells.

scientific article published on 29 March 2018

List of works by Min H Kang

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma

A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines.

Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines.

Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia

Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines

Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia

DNA-PK as an Emerging Therapeutic Target in Cancer

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program ⬇️

Fenretinide cytotoxicity is independent of both constitutive and pharmacologically modulated glutathione levels in pediatric acute lymphoblastic leukemia cells cultured at hypoxia.

Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure

Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models

Hydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma

Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

Initial testing of aplidin by the pediatric pre-clinical testing program.

Initial testing of lenalidomide by the pediatric preclinical testing program

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

Initial testing of topotecan by the pediatric preclinical testing program.

MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma

Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma

Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas

Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.